Helix BioPharma Corp. (HBPCF)
| Market Cap | 53.21M -59.3% |
| Revenue (ttm) | n/a |
| Net Income | -2.44M |
| EPS | -0.03 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Open | 0.7700 |
| Previous Close | 0.7700 |
| Day's Range | 0.7700 - 1.7100 |
| 52-Week Range | 0.7700 - 1.7340 |
| Beta | -0.14 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Oct 28, 2026 |
About Helix BioPharma
Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is ... [Read more]
News
Early Warning Press Release Regarding The Disposition Of Common Shares Of Helix Biopharma Corp. By Jerzy Wilczewski
Vancouver, October 19, 2026 - TheNewswire – Mr. Jerzy Wilczewski announces the disposition of 800,000 common shares (“Common Shares”) in the capital of Helix Biopharma Corp. (“Helix” or the “Corporati...
Helix BioPharma Corp. Appoints Markus Loeffler, MD, MBA, as Chief Medical Officer to Support Next Phase of Clinical Development
Vancouver, British Columbia – TheNewswire - August 17, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPC F ” , FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology comp...
Helix Biopharma Corp. Announces Board Composition Changes
Vancouver, British Columbia; August 14, 2026 – TheNewswire - Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company...
Helix BioPharma Corp. Strengthens Executive Leadership to Support U.S. Listing Strategy and Next Phase of Clinical Development
Vancouver, British Columbia – TheNewswire - June 30 , 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company...
Helix Biopharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Nine-Month Periods Ended April 30, 2026
Vancouver, British Columbia – TheNewswire - June 12, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company ...
Helix BioPharma Corp. Announces Closing of Private Placement of Convertible Debentures
Vancouver, British Columbia – TheNewswire - 3 June, 2026 – Helix BioPharma Corp. (TSX: “ HBP ”, OTC PINK: “ HBPCF ”, FRANKFURT: “ HBP0 ”) (“ Helix ” or the “ Company ”), a clinical-stage oncology comp...
Helix BioPharma Corp. Announces Grant and Cancellation of Stock Options
Toronto, Ontario – TheNewswire - May 22, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping a ne...
Helix Biopharma Corp. Announces Strategic Board and Governance Appointments to Support Financing and Nasdaq Uplisting Strategy
Toronto, Ontario – TheNewswire - 13 May, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping a ne...
Helix BioPharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026
Toronto, Ontario – TheNewswire - 16 March, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping a ...
Helix BioPharma Corp. Announces Presentation at 16th Annual World ADC London
Toronto, Ontario – TheNewswire - February 24, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping...
Helix Biopharma Corp. Extends LEUMUNA Option with metaShape Pharma for Adipose Tissue-Related and Metabolic Diseases
(Toronto, Ontario; February 5, 2026) – TheNewswire - Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping...
Helix BioPharma Corp. Announces Voting Results from its Annual General and Special Meeting
Toronto, Ontario – TheNewswire - 30 January, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC: “HBPCF” , FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping a nea...
Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three-Month Period Ended October 31, 2025
Toronto, Ontario – TheNewswire - 15 December, 2025 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping...
Helix BioPharma Corp. Announces Fiscal 2025 Year-End Results
Toronto, Ontario – TheNewswire - 29 October 2025 – Helix BioPharma Corp. (TSX: “HBP”, OTC: “HBPCF”, FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping a near fu...
Jerzy Wilczewski Announces Acquisition of Common Shares of Helix Biopharma Corp.
VANCOUVER, BC / ACCESSWIRE / April 22, 2022 / Mr. Jerzy Wilczewski announces the acquisition of 7,700,000 common shares ("Common Shares") in the capital of Helix Biopharma Corp. ("Helix" or the "Compa...
Helix Biopharma Corp. Closes Private Placement
RICHMOND HILL, ON / ACCESSWIRE / April 21, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of imm...
Helix Biopharma Corp. Announces Appointment of Permanent CEO and Independent Board Members
RICHMOND HILL, ON / ACCESSWIRE / April 18, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of imm...
Helix Biopharma Corp. Announces Extension of Early Warrant Exercise Incentive Program and Receipt of Private Placement Subscription
RICHMOND, ON / ACCESSWIRE / April 13, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-o...
Helix Biopharma Corp. Announces Management and Board Changes
RICHMOND HILL, ON / ACCESSWIRE / March 22, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of imm...
Helix Biopharma Corp. Announces Fiscal 2022 Second Quarter Results
RICHMOND, ON / ACCESSWIRE / March 16, 2022 / Helix BioPharma Corp. (TSX:HBP), (" Helix " or the " Company "), a clinical-stage biopharmaceutical company developing unique therapies in the field of imm...
Helix Biopharma Corp. Announces Unexpected Passing of Interim CEO and Chairman of the Board
RICHMOND HILL, ON / ACCESSWIRE / March 16, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company") today announces, with great sadness, the sudden passing of its Interim Chief Executive Offi...
CORRECTION: Helix Biopharma Corp. Closes Private Placement and Announces Early Warrant Exercise Incentive Program and Extension of Warrant Exercise Period
(This release corrects the release that was posted earlier on March 11, 2022 due to the incorrect company logo being added. This release adds the corrected logo) RICHMOND HILL, ON / ACCESSWIRE / March...
Helix Biopharma Corp. Closes Private Placement and Announces Early Warrant Exercise Incentive Program and Extension of Warrant Exercise Period
RICHMOND HILL, ON / ACCESSWIRE / March 11, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of imm...
Helix BioPharma Corp. Provides Corporate Update
RICHMOND HILL, ON / ACCESSWIRE / December 31, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and...
Helix BioPharma Corp. Extends Period to Exercise Warrants
RICHMOND HILL, ON / ACCESSWIRE / December 14, 2021 / Helix BioPharma Corp. (TSX:HBP)(FSE:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the preve...